Nusano will supply copper-64 to Clarity Pharmaceuticals from its West Valley City, Utah facility, enabling commercial-scale production of next-gen radiopharmaceuticals for prostate cancer diagnostics in the U.S.
West Valley City, Utah-based Isotope manufacturer Nusano has signed a commercial supply agreement with Clarity Pharmaceuticals, securing large-scale copper-64 (Cu-64) production for next-generation cancer diagnostics in the U.S.
Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancers.
Copper-64 is a radioactive isotope of copper used primarily in medical imaging, especially positron emission tomography (PET) scans for cancer diagnostics. With a half-life of approximately 12.7 hours, it offers a practical balance—long enough for centralized production and same-day delivery to imaging sites, but short enough to minimize long-term radiation exposure. It emits positrons for imaging and also has beta-emitting capabilities, making it suitable for theranostic applications that combine diagnosis and therapy. Compared to shorter-lived isotopes like fluorine-18 or gallium-68, copper-64 enables broader geographic reach and more flexible scheduling, critical for commercial-scale radiopharmaceutical deployment. It’s particularly useful in prostate cancer imaging, such as in Clarity Pharmaceuticals’ SAR-bisPSMA, and is gaining traction across oncology for its scalability, reliability, and compatibility with Big Pharma-style supply chains.
Under the deal, Nusano will deliver copper-64 from its upcoming 190,000-square-foot facility in West Valley City, Utah. The site is expected to go live in 2025, with isotope shipments starting in early 2026. The company’s proprietary accelerator-based tech allows for high-throughput manufacturing — more than 1,000 curies (37,000 GBq) of copper-64 per day — enough to meet demand for over 18,000 patient doses daily.
The agreement supports the commercial rollout of Clarity’s lead diagnostic, SAR-bisPSMA, a copper-64–based PET imaging agent targeting prostate-specific membrane antigen (PSMA) in men with prostate cancer.
Clarity Executive Chairperson Dr. Alan Taylor said the deal “locks in a cost-effective and abundant U.S. supply of copper-64,” and that with late-stage trials progressing, “we’re now ready for commercial rollout at scale — not just in theory, but in practice.” He added, “We’ve seen the limitations of short-lived tracers firsthand. This is about solving for that — and building an oncology model that works like big pharma expects.”
Nusano, a privately held physics company committed to bringing supply stability and innovation to the rapidly emerging and critically undersupplied medical radioisotopes market, is also advancing domestic production of nickel-64, copper-67, and actinium-225 — all isotopes used in Clarity’s theranostic pipeline. The company’s broader platform will eventually support the production of over 25 medical isotopes for diagnostics and therapy.
“We’re excited to partner with Clarity and enable their clinical and commercial efforts with dependable, high-volume isotope supply,” said Nusano CEO Chris Lowe.
With three FDA Fast Track designations already granted for SAR-bisPSMA, Clarity is now positioned to submit New Drug Applications and scale its Targeted Copper Theranostics (TCTs) platform across the U.S. healthcare market.
Additional Disclosure:
The Supply Agreement is effective as of 16 April 2025 and is for an initial period of 3 years with automatic renewal for successive 2-year periods. Cancellation provisions are aligned with industry standard rates.
For more information, visit nusano.com and www.claritypharmaceuticals.com